Head and neck cancer is
the 6th most common cancer

430
people
K
are living with oral cavity and Pharyngeal cancer (high risk)
55
cases
K
of oral cancer are detected annually
12
deaths
K
from head and neck cancer occur annually
25
25 to 40 %
late stage 5-year survival rate

Introducing Oro Lesion

Oro Lesion is a non-invasive, salivary-rinse DNA test designed to detect early markers of oral cancer—before symptoms emerge. The test is an indicated adjunct test for early diagnosis of Oral Cavity Squamous Cell Carcinoma (OCSCC) in anyone over the age of 18 with a visible indeterminate lesion in the oral cavity.

See how it works Click to view See how it works
Product Features Container (1)

Coupled with the Oris Bridge digital health patient navigator

 

CLINICAL INTERVENTION
  • Navigate patient care to an oral surgeon
PATIENT EDUCATION
  • Provide patients and caregivers insights on the management of oral cancer to make it less stressful
CLAIM AUTOMATION
  • Medical claims submitted accurately and approved quickly, leaving clinical staff to focus on patient health
INSURANCE REVIEW
  • Gives objective guide to efficiently review claims to reduce administrative work

Early and accurate detection improves outcomes

icon-person-cross
Improved survival rate

Timely intervention significantly enhances treatment outcomes

logo-hand-heart
Minimal intervention

Early-stage OCSCC can often be effectively treated with minor surgical procedures

logo-bank
Reduced costs

Early detection lowers financial burden for patients and healthcare systems

light bule x sign
Try Oro Lesion today.
Contact us